Bionomics’ BNC210 anti-anxiety drug enters phase I
Friday, 21 December, 2012
Bionomics’ (ASX:BNO) US partner, Ironwood Pharmaceuticals, has moved forward with development of anti-anxiety drug IW-2143, also known as BNC210, by initiating a phase I trial.
The company filed an Investigational New Drug application with the Food and Drug Administration in November.
The phase I trial will assess safety and pharmacokinetics of BNC210 in healthy volunteers using single and multiple doses.
“This is the first US clinical trial of IW-2143 and this news is welcomed by Bionomics as a strong signal of the progress being made by Ironwood in moving ahead with the study of IW-2143,” said Bionomics CEO and MD, Dr Deborah Rathjen.
Bionomics is expecting a US$2m milestone payment from Ironwood as the trial progresses.
Bionomics’ (ASX:BNO) lost half a cent in morning trading, sitting at 35c as of around 11am Friday.
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
Prenatal stress leaves a molecular mark on newborns
An international study has uncovered how stress experienced during pregnancy can affect newborns...
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
